Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + denosumab
- Development stage
- Phase 2
- Lead developer
- Eisai
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
A combination therapy of lenvatinib and denosumab. Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that targets VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET, inhibiting pathogenic angiogenesis and tumor growth. Denosumab is a fully human monoclonal antibody that binds to RANKL, blocking osteoclast maturation, function, and survival, thereby reducing bone resorption. This combination is being studied specifically for bone-predominant metastatic radioiodine refractory differentiated thyroid carcinomas.
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on lenvatinib + denosumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + denosumab.